Been flat out this week, just catching up on msb now. Lots of...

Been flat out this week, just catching up on msb now. Lots of great posts to read over and volume >3.3M today, wow. I'd be licking my chops if I had more cash to invest, but I don't - so wouldn't mind seeing the sp slowly go up again! Someone's gobbling up loads of shares.

The main point is Revascor's going to phase III - One step closer to commercialisation, so great news. Aside from Craig Collie, and BBY (lol), most analysts and medical folk agree the results are very positive.

Snippets from the bloomberg article:

"The data was “outstanding,” Stuart Roberts, an analyst at Bell Potter Securities. “This is probably the biggest thing in heart failure in 10 years.”

"The phase II trial result reinforces “Teva’s commitment to its strategic investment in Mesoblast’s adult stem cell technology and to our continued support for the clinical development of Revascor,” Teva's Kevin Buchi."

“In any clinical trial, the full data needs to be examined,” Craig Collie, an analyst at Macquarie Group Ltd., said. “In this instance, the trial missed every pre-defined efficacy endpoint, except for major adverse cardiac event.”

"Collie raised the possibility that Teva Pharmaceutical Industries Ltd. (TEVA), Mesoblast’s partner for developing the drug, and the U.S. Food and Drug Administration may not provide funding and clearance for a phase III trial to proceed." (hahaha)

Don't worry Craig, one day you might just begin to understand Mesoblast, stem cells and FDA trials - it's okay, there no rush.

On balance I believe it's status quo for MSB, onward and eventually upward..